Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis

Safety profile of vascular endothelial growth factor receptor tyrosine-kinase inhibitors in pediatrics: a pharmacovigilance disproportionality analysis

Introduction: existing research on children consists primarily of phase I/II clinical trials for VEGFR-TKI. System reports of safety on the use of VEGFR-TKI in pediatrics are lacking.Aim: to investigate the safety profiles of VEGFR-TKI in pediatrics via the FDA Adverse Event Reporting System (FAERS)...

Full description

Bibliographic Details
Main Authors: Yifei Xue, Shuo Feng, Guangyao Li, Chao Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Pharmacology
Subjects:
pharmacovigilance
FDA adverse event reporting system (FAERS)
VEGFR tyrosine kinase inhibitors
pediatrics
adverse event (AE)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1160117/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1160117/full

Similar Items